Previous 10 | Next 10 |
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present additional preclinical data on SNS-101, a ...
2023-08-03 10:21:20 ET Sensei Biotherapeutics press release ( NASDAQ: SNSE ): Q3 GAAP EPS of -$0.31. Cash, cash equivalents and marketable securities were $78.8 million as of June 30, 2023, as compared to $107.1 million as of December 31, 2022. For further details se...
Phase 1/2 clinical trial enrolling for lead investigational candidate SNS-101, a conditionally active VISTA-blocking antibody for the treatment of advanced solid tumors A total of 6 patients in three dosing cohorts enrolled to date, with initiation of combination arm now planned for Q4 ...
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a fireside chat...
- Featuring Dr. James Gulley, Co-Director of the Center for Immuno-Oncology at the National Cancer Institute (NCI) and internationally recognized expert on cancer immunotherapy - - Pre-registration available for live event, to be held Tuesday, June 27, 2023 at 2:00 p.m. ET - BOSTO...
- Topline Phase 1 monotherapy and initial combination data expected in 2024 - BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...
BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, wil...
2023-05-09 08:52:05 ET Sensei Biotherapeutics press release ( NASDAQ: SNSE ): Q1 GAAP EPS of -$0.33 beats by $0.02 . Cash, cash equivalents and marketable securities were $95.5 million as of March 31, 2023, as compared to $107.1 million as of December 31, 2022. Sensei ...
- Investigational New Drug (IND) application for SNS-101 cleared by U.S. Food and Drug Administration (FDA) with first patient dose in Phase 1/2 trial expected in mid-2023 - - Signing of key collaborations underscore potential of conditional activation and VISTA mechanism - - AA...
2023-04-21 13:53:45 ET Gainers: Presto Automation ( PRST ) +49% . CBL International Limited ( BANL ) +34% . EyePoint Pharmaceuticals EYPT +31% . Asset Entities ( ASST ) +25% . ContextLogic ( WISH ) +24% . Mullen Automotive ( MU...
News, Short Squeeze, Breakout and More Instantly...
Sensei Biotherapeutics Inc. Company Name:
SNSE Stock Symbol:
NASDAQ Market:
2024-05-13 18:15:04 ET Stephens analyst issues OVERWEIGHT recommendation for SNSE on May 13, 2024 04:20PM ET. SNSE was trading at $1.57 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendati...
2024-05-13 18:00:03 ET Sudan Loganathan from Stephens issued a price target of $5.00 for SNSE on 2024-05-13 16:20:00. The adjusted price target was set to $5.00. At the time of the announcement, SNSE was trading at $1.57. The overall price target consensus is at $6.00 wi...
- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion...